Suppression of Collagen-Induced Arthritis by Natural Killer T Cell Activation with OCH, a Sphingosine-Truncated Analog of α -Galactosylceramide

Arthritis and Rheumatism

Volumn 50, Issue 1, 2004, Pages 305-313

  Chiba, Asako ^a   Oki, Shinji ^b   Miyamoto, Katsuichi ^b   Hashimoto, Hiroshi ^a   Yamamura, Takashi ^b   Miyake, Sachiko ^b  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; COLLAGEN ANTIBODY; COLLAGEN TYPE 2; GLYCOLIPID; INTERLEUKIN 10; INTERLEUKIN 4; MONOCLONAL ANTIBODY; SPHINGOSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; LYMPHOCYTE ACTIVATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; TH2 CELL;

ANIMALS; ARTHRITIS, EXPERIMENTAL; GALACTOSYLCERAMIDES; INTERLEUKIN-10; INTERLEUKIN-4; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SPHINGOSINE; TH2 CELLS;

EID: 0346458555     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11489     Document Type: Article

References (45)

1. Van Roon JAG, Lafeber FPJG, Bijlsma JWJ. Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum 2001;44:3-12.
2. Walmsley M, Katsikis PD, Abney E, Parry S, Williams RO, Maini RN, et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996;39:495-503.
3. Joosten LAB, Lubberts E, Durez P, Helsen MMA, Jacobs MJM, Goldman M, et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis: protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997;40:249-60.
4. Horsfall AC, Butler DM, Marinova L, Warden PJ, Williams RO, Maini RN, et al. Suppression of collagen-induced arthritis by continuous administration of IL-4. J Immunol 1997;159:5687-96.
5. Apparailly F, Verwaerde C, Jacquet C, Auriault C, Sany J, Jorgensen C. Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. J Immunol 1998;160:5213-20.
6. Ma Y, Thornton S, Duwel LE, Boivin GP, Giannini EH, Leiden JM, et al. Inhibition of collagen-induced arthritis in mice by viral IL-10 gene transfer. J Immunol 1998;161:1516-24.
7. Lubberts E, Joosten LAB, van den Bersselaar L, Helsen MMA, Bakker AC, van Meurs JBJ, et al. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction. J Immunol 1999;163:4546-56.
8. Setoguchi K, Misaki Y, Araki Y, Fujio K, Kawahata K, Kitamura T, et al. Antigen-specific T cells transduced with IL-10 ameliorate experimentally induced arthritis without impairing the systemic immune response to the antigen. J Immunol 2000;165:5980-6.
9. Lubberts E, Joosten LAB, Chabaud M, van den Bersselaar L, Oppers B, Coenen-de Roo CJJ, et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000;105:1697-710.
10. Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 2001;166:3499-505.
11. Morita Y, Yang J, Gupta R, Shimizu K, Shelden EA, Endres J, et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001;107:1275-84.
12. Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997;15:535-62.
13. Hong S, Scherer DC, Singh N, Mendiratta SK, Serizawa I, Koezuka Y, et al. Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice. Immunol Rev 1999;169:31-44.
14. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2000;21:573-83.
15. Sumida T, Sakamoto A, Murata H, Makino Y, Takahashi H, Yoshida S, et al. Selective reduction of T cells bearing invariant Vα24JαQ antigen receptor in patients with systemic sclerosis. J Exp Med 1995;182:1163-8.
16. Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, et al. Extreme Thl bias of invariant Vα24JαQ T cells in type 1 diabetes. Nature 1998;391:177-81.
17. Illes Z, Kondo T, Newcombe J, Oka N, Tabira T, Yamamura T. Differential expression of NK T cell Vα24JαQ invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol 2000;164:4375-81.
18. Kojo S, Adachi Y, Keino H, Taniguchi M, Sumida T. Dysfunction of T cell receptor AV24AJ18+,BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum 2001;44:1127-38.
19. Yoshimoto T, Bendelac A, Hu-Li J, Paul WE. Defective IgE production by SJL mice is linked to the absence of CD4+, NK1.1+ T cells that promptly produce interleukin 4. Proc Natl Acad Sci U S A 1995;92:11931-4.
20. + NK T cells associated with disease development in autoimmune-prone mice. J Immunol 1996;156:4035-40.
21. +-like thymocytes in the NOD mouse. Eur J Immunol 1996;26:2989-98.
22. Hong SH, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV, et al. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001;7:1052-6.
23. Singh AK, Wilson MT, Hong S, Olivares-Villagomez D, Du C, Stanic AK, et al. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med 2001;194:1801-11.
24. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, et al. CD1d-restricted and TCR-mediated activation of Vα14. Nature 1998;391:177-81.
25. Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P, et al. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998;188:1521-8.
26. Spada FM, Koezuka Y Porcelli SA. CD1d-restricted recognition of syntheic glycolipid antigens by human natural killer T cells. J Exp Med 1998;188:1529-34.
27. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing Th2 bias of natural killer T cells. Nature 2001;413:531-4.
28. Pal EA, Tabira T, Kawano T, Taniguchi M, Miyake S, Yamamura T. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of Vα14+ NK T cells. J Immunol 2001;166:662-8.
29. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunization against heterologous type II collagen induces arthritis in mice. Nature 1980;283:666-8.
30. Campbell IK, Rich MJ, Bischof RJ, Dunn AR, Grail D, Hamilton JA. Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J Immunol 1998;161:3639-44.
31. b) mice: new insights into an important disease model of rheumatoid arthritis. Eur J Immunol 2000;30:1568-75.
32. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, et al. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 1997;278:1623-6.
33. Sharif S, Arreaza GA, Zucker P, Mi Q-S, Sondhi J, Naidenko OV, et al. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat Med 2001;7:1057-62.
34. Mempel M, Ronet C, Suarez F, Gilleron M, Puzo G, van Kaer L, et al. Natural killer T cells restricted by the monomorphic MHC class 1b CD1dl molecules behave like inflammatory cells. J Immunol 2002;168:365-71.
35. Hammond KJL, Poulton LD, Palmisano LJ, Silveria PA, Godfrey DJ, Bazter AG. α/β-T cell receptor (TCR)+CD4-CD8-(NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med 1998;187:1047-56.
36. Lehuen A, Lantz O, Beaudoin L, Laloux V, Carnaud C, Bendelac A, et al. Overexpression of natural killer T cells protects Vα14Jα281 transgenic nonobese diabetic mice against diabetes. J Exp Med 1998;188:1831-9.
37. Wang B, Geng YB, Wang CR. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med 2001;194:313-9.
38. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-31.
39. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
40. Brennan FM, Maini RN, Feldmann M. TNF alpha: a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992;31:293-8.
41. Criscione LG, St Clair EW, Tumor necrosis factor-α antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002;14:204-11.
42. Kong Y-Y, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9.
43. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250-8.
44. Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay R, Gay S. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000;43:2523-30.
45. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, et al. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000;43:259-69.